Nec Corporation

Tokyo Medical University

Other

Japan Science and Technology Agency

The University of Tokyo

Tokyo Medical and Dental University

Bonac Corporation

Accural Inc.

Mbc, Inc.

Masahiko Kuroda

Hokkaido University

Kuroda, Masahiko

Mizutani, Takayuki

Makoto Watanabe

Akira Saito

Kosuke Oikawa

Masakatsu Takanashi

Yoshinori Kosugi

Masami Tanaka

Shinichiro Ohno

Takayuki Mizutani

Seiko Iizuka

Kazuma Ohyashiki

Akihiko Tsuchida

Keiichi Yoshida

Tadaaki Ohgi

Tomoharu Kiyuna

Eriko Aoki

Kenji Okajima

Hiroaki Torii

Shiori Kato

Yasuhiko Yoshida

Tomohiro Umezu

Shin-ichiro Ohno

Noriko Gotoh

Tetsuya Ohbayashi

Kiyoshi Mukai

Ken' Ichi Kamijo

Nobuo Tsuchida

Hidekazu Toyofuku

Atsuhiro Kanda

Susumu Ishida

Provided is a novel carrier for introducing a nucleic acid such as a siRNA into a cell. The carrier for a nucleic acid of the present invention includes vesicles from a plant in the family Malpighiaceae, and preferably vesicles derived from acerola. A method for administering a nucleic acid according to the present invention includes forming a conjugate of the carrier for a nucleic acid of the present invention and a nucleic acid and administering the conjugate.

Nucleic acid carrier and method for administering nucleic acid

The invention provides an artificial match-type miRNA utilizing miRNA. In particular, the invention provides a single strand nucleic acid containing an X region and a Y region, wherein the 3'-terminal of the X region and the 5&#x2032;-terminal of the Y region are linked via a linker region of a non-nucleotide structure, the X region contains a guide strand sequence of a mature miRNA, and the Y region contains a sequence completely complementary to the X region is an artificial match-type miRNA. The artificial match-type miRNA can suppress expression of the target gene.

Artificial match-type miRNA for controlling gene expression and use therefor

The present disclosure is directed to an artificial mimic miRNA utilizing miRNA. An artificial mimic miRNA is a single-stranded nucleic acid including: a X region; and a Y region, the Y region and the X region being linked, wherein the X region is a guide strand sequence of a mature miRNA or a partial sequence of the guide strand sequence of the mature miRNA and consists of a linking side region (X) and a non-linking side region (X) to the Y region, the linking side region (X) is a sequence that does not cause intramolecular annealing within its region, and the Y region is a sequence that intramolecularly anneals to the non-linking side region (X) of the X region. According to the artificial mimic miRNA of the present invention, the expression of the target gene can be inhibited.

Artificial mimic miRNA for controlling gene expression, and use of same

The present invention provides a novel cancer marker for evaluating the onset, the preclinical stage, the clinical stage, or the prognosis of a cancer in a subject, and an evaluation method using the same. A cancer marker containing at least one miRNA selected from hsa-miR-92 and hsa-miR-494 is used as a marker for cancers excluding breast cancer. A method for evaluating the possibility of cancers excluding breast cancer includes the step of detecting the expression level of a cancer marker in a biological sample collected from a subject. In this method, the cancer marker contains at least one miRNA selected from hsa-miR-92 and hsa-miR-494.

Cancer marker, method for evaluation of cancer by using the cancer marker, and evaluation reagent

Disclosed is an identification marker which can be utilized for detection of various human cancer cells and whose expression closely relates to malignant alteration of cells, and compositions for human cancer treatment which are based on suppression of cancer cell proliferation through inhibition of expression of the identification marker. The marker is human heterochromatin protein 1&#x3b3; (HP1&#x3b3;), and the compositions for cancer treatment comprises one or more agents which suppresses the expression of human HP1&#x3b3; gene, such as siRNAs to human HP1&#x3b3;.

Cancer cell identification marker and cancer cell proliferation inhibitor

An object of the present invention is to provide a method for inhibiting activation of signaling pathway mediated by erbB1 or erbB2 in human cell and a signaling inhibitor to be used therefor. The above-described activation of signaling pathway can be inhibited by a polypeptide comprising at least one of PTB domain or ERK2 binding domain of human FRS2&#x3b2;. The above-described polypeptide may be introduced directly into cell, or nucleic acid which encodes for the above-described polypeptide may be introduced into cell to allow expression of the polypeptide in the cell. Such polypeptide and nucleic acid can be used, for example, as a signaling inhibitor. In addition, since erbB1 and erbB2 are involved in development of cancer, the above-described signaling inhibitor is also useful, for example, as an anticancer drug.

Method for inhibiting signal transduction, signal transduction inhibitor to be used therein and use thereof

The present invention identifies the total nucleotide sequence of a novel oncogene from human, which is directly involved in such a cancerization mechanism as for cervical cancer induced by HPV infection of cervical epithelial cell and the amino acid sequence of an oncogenic protein encoded thereby, and to provide a full-length polynucleotide encoding a peptide chain of the oncogenic protein derived from the novel oncogene, which can be used for recombinant production of the oncogenic protein, and the peptide chain of the oncogenic protein produced recombinantly therewith. Specifically, the present invention provides a novel oncogene polynucleotide from human involving development of cervical cancer, comprising a nucleotide sequence encoding an amino acid sequence of SEQ. ID. No. 1, particularly a polynucleotide of the nucleotide sequence of SEQ. ID. No. 2.

Sirna capable of inhibiting the expression of an oncogene involved in cervical cancer

A method of evaluating a cell state based on information of an image taken of a cell containing a chromosome territory is provided. This method includes extracting the chromosome territory from the image (S), standardizing a positioning state of the chromosome territory and then quantifying the positioning state (S), and evaluating the cell state based on the quantified positioning state of the chromosome territory (S).

Method of evaluating chromosome state and evaluation system

The expression level of a histamine-releasing factor (HRF) polynucleotide in a biological sample of a subject is measured and the HRF polynucleotide content is compared with that of a normal biological sample. An HRF polynucleotide expression level considerably higher than that of the normal biological sample is employed as an indication of a disease relating to endometriosis or a risk thereof.

Method of diagnosing disease relating to endometriosis

The present invention identifies the total nucleotide sequence of a novel oncogene from human, which is directly involved in such a cancerization mechanism as for cervical cancer induced by HPV infection of cervical epithelial cell and the amino acid sequence of an oncogenic protein encoded thereby, and to provide a full-length polynucleotide encoding a peptide chain of the oncogenic protein derived from the novel oncogene, which can be used for recombinant production of the oncogenic protein, and the peptide chain of the oncogenic protein produced recombinantly therewith. Specifically, the present invention provides a novel oncogene polynucleotide from human involving development of cervical cancer, comprising a nucleotide sequence encoding an amino acid sequence of SEQ. ID. No.1, particularly a polynucleotide of the nucleotide sequence of SEQ. ID. No.2.

Oncogene, recombinant protein derived therefrom, and uses thereof

Growing community of inventors

Tokyo, Japan

Masahiko Kuroda